Pazopanib

Pazopanib
Clinical data
License data	EU EMA: by INN; US FDA: Pazopanib;
Routes of; administration	Oral
ATC code	L01XE11 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	>99%
Metabolism	Hepatic (CYP3A4, 1A2 and 2C8-mediated)
Elimination half-life	31 hours (mean)
Excretion	Mostly fecal
Identifiers
	IUPAC name 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzolsulfonamide;
CAS Number	444731-52-6;
PubChem CID	11525740;
ChemSpider	8289501;
CompTox Dashboard (EPA)	DTXSID8048733 ;
Chemical and physical data
Formula	C21H23N7O2S
Molar mass	437.517 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc3ccc(cc3S(N)(=O)=O)Nc(ncc4)nc4N(C)c(cc1nn2C)ccc1c2C;

Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis. It has been approved for renal cell carcinoma by the U.S. Food and Drug Administration.^[1] Pazopanib may also be active in ovarian cancer^[2] and soft tissue sarcoma.^[3] Pazopanib also appears effective in the treatment of non-small cell lung carcinoma.^[2]

References

^ "FDA Approves GlaxoSmithKline's Votrient(TM) For Advanced Renal Cell Cancer". Medical News Today. 20 October 2009. Retrieved 8 June 2010.
^ ^a ^b "Pazopanib shows encouraging activity in several tumour types, including soft tissue sarcoma and ovarian cancer". FierceBiotech. 2008-09-15. Retrieved 2010-08-10.
^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1200/JCO.2008.21.3223, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1200/JCO.2008.21.3223 instead.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.